Clinical trials: Corneal Defect
Anterior Chamber Inflammation, Ocular Pain
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery
- Conditions
- Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect
- Trial name
- NCT04975971
- Testing
- Dextenza 0.4Mg Ophthalmic Insert
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nicole Fram M.D.
Corneal Epithelial Defects After Ocular Surgeries
Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Topical insulin application has been proved recently to increase corneal reepithelization rate over diabetic animals. However, its effectiveness on corneal epithelial wound healing in patients who received pars planar vitrectomy…
- Trial name
- NCT01031888
- Testing
- Topical insulin eye drops, Conventional postoperative eye drops
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Taiwan University Hospital
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Persistent Corneal Epithelial Defect
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.
- Trial name
- NCT00988494
- Testing
- DE-105 ophthalmic solution
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Persistent Corneal Epithelial Defect
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED).
- Trial name
- NEXPEDE-1 (NCT05966493)
- Testing
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Where
- 28 sites in United States, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- Glaukos Corporation
Corneal Ulcer, Corneal Perforation
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Purpose: To evaluate the clinical outcome of patients with refractory Neurotrophic Keratopathy (NK) in stages 2 and 3 treated with topical insulin.
- Conditions
- Corneal Ulcer, Corneal Perforation, Corneal Epithelium Defect, Neurotrophic Keratitis
- Trial name
- NCT04820010
- Testing
- Topical Insulin
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.